Couverture de Clinical and Experimental Ophthalmology Conversations

Clinical and Experimental Ophthalmology Conversations

Clinical and Experimental Ophthalmology Conversations

De : Victoria Cartwright
Écouter gratuitement

À propos de ce contenu audio

"Clinical and Experimental Ophthalmology Conversations” is the official podcast of Clinical & Experimental Ophthalmology. It provides in-depth, behind-the-scenes interviews with authors of hot topic papers from the journal. Each episode discusses a recently published manuscript, highlighting key findings, clinical impact and how new evidence is shaping ophthalmic practice. Designed for ophthalmologists, orthoptists, optometrists and nurses, the series bridges research with real-world application. “CEO Conversations” delves into authors’ personal perspectives, areas of debate and insights into the future of the field of ophthalmology. Subscribe and listen to stay at the forefront of innovation in ophthalmology.Copyright 2026 Victoria Cartwright Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Episode 2: Tattoo Associated Uveitis - More Common than you Might Realise
      Feb 10 2026
      This large case series from Australia reviews 40 patients with tattoo associated uveitis. Most cases were found to be bilateral. Although all forms of uveitis are possible, anterior uveitis is the most common presentation, occurring in 70% of eyes. Vision was commonly affected, such that two-thirds of patients required long term immunosuppression. Given that 25% of the Australian population has a tattoo, asking for this is a critical question in any patient presenting with uveitis.
      Afficher plus Afficher moins
      17 min
    • Episode 1: Dominant Optic Atrophy - in Search of Biomarkers
      Dec 1 2025
      A recent systematic review and meta-analysis of studies on dominant optic atrophy found that visual acuity was the only biomarker with longitudinal data, and its rate of change did not differ significantly from zero. These findings highlight a critical gap in the field - robust, sensitive biomarkers capable of capturing disease progression are lacking. Identifying alternative structural, functional or molecular biomarkers will be essential for designing and validating future therapeutic clinical trials in dominant optic atrophy.
      Afficher plus Afficher moins
      22 min
    Aucun commentaire pour le moment